Handelsbanken Fonder AB Buys New Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Handelsbanken Fonder AB purchased a new position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 13,500 shares of the company’s stock, valued at approximately $205,000.

Several other hedge funds have also recently made changes to their positions in the business. Eventide Asset Management LLC boosted its position in shares of Zentalis Pharmaceuticals by 13.6% during the 3rd quarter. Eventide Asset Management LLC now owns 7,814,039 shares of the company’s stock valued at $156,750,000 after purchasing an additional 936,236 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Zentalis Pharmaceuticals by 6.2% during the 3rd quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company’s stock worth $105,047,000 after buying an additional 307,490 shares in the last quarter. Federated Hermes Inc. grew its position in shares of Zentalis Pharmaceuticals by 10.9% during the 4th quarter. Federated Hermes Inc. now owns 2,160,565 shares of the company’s stock worth $32,733,000 after buying an additional 212,872 shares during the period. Sectoral Asset Management Inc. increased its stake in shares of Zentalis Pharmaceuticals by 65.2% in the 3rd quarter. Sectoral Asset Management Inc. now owns 386,525 shares of the company’s stock valued at $7,754,000 after acquiring an additional 152,525 shares in the last quarter. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter valued at $2,836,000.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ZNTL shares. Wedbush raised their price target on shares of Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the stock a “neutral” rating in a report on Wednesday, February 28th. HC Wainwright restated a “buy” rating and issued a $46.00 target price on shares of Zentalis Pharmaceuticals in a research note on Wednesday, February 28th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $38.57.

Insider Activity at Zentalis Pharmaceuticals

In related news, CFO Melissa B. Epperly sold 2,573 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $11.44, for a total value of $29,435.12. Following the completion of the transaction, the chief financial officer now directly owns 451,449 shares in the company, valued at approximately $5,164,576.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.10% of the stock is currently owned by corporate insiders.

Zentalis Pharmaceuticals Price Performance

NASDAQ:ZNTL opened at $11.71 on Friday. The firm has a 50-day moving average of $13.89 and a 200-day moving average of $13.63. The company has a market cap of $831.53 million, a PE ratio of -2.58 and a beta of 1.82. Zentalis Pharmaceuticals, Inc. has a one year low of $9.56 and a one year high of $31.46.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.09. On average, equities research analysts expect that Zentalis Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.